Therapeutic Effects of Gut Microbiota on Metabolic Syndrome: A Patent
Review

Shivani      Singhal; Vibha      Rani

doi:10.2174/2212798412666220318162322

Abstract

Background: The balanced composition of the gut microbiota is essential for human health. The dysbiotic condition may develop various complex diseases. A metabolic syndrome is a group of biochemical and physiological abnormalities that can increase the risk of cardiovascular diseases, diabetes, and inflammatory diseases. It has become a serious concern worldwide because there is no acceptable medication to overcome this problem.

Objective: This review aims to evaluate the relationship between gut microbiota and metabolic syndrome. The balance of gut microbiota relates to human health as well as diseases. Patents related to significant findings on probiotics, prebiotics, synbiotics, and fecal microbiota transplantation signify the importance of the proposed theme and provide promising therapeutic strategies to modulate the dysbiotic condition and reoccurrence of beneficial microbial species during metabolic syndromes. Screening of patents-related databases can be worth full to track new technology. Therefore, some selected recent patents related to gut microbiota and associated therapies have been discussed in the present manuscript.

Conclusion: Under the existing situation, the role of gastrointestinal microbiota as a therapeutic agent is becoming more utilized for treating human health issues and various metabolic syndromes including obesity, diabetes, and cardiovascular diseases. Understanding gut dysbiosis and associated complex interactions between microbes and hosts would be effective for designing future therapeutic interventions for metabolic syndrome. Our detailed patent analysis reflects that gut dysbiosis has a prominent role in metabolic syndromes and dietary therapeutic strategies can improve health by modulating the human microbiota, their metabolites ad stability.

Keywords: Metabolic syndrome, gut microbiota, microbial metabolites, probiotics, prebiotics, synbiotics, fecal microbiota transplantation.

« Previous Next »

Graphical Abstract

[1]
Samson, S.L.; Garber, A.J. Metabolic syndrome. Endocrinol. Metab. Clin. North Am.,  2014, 43(1), 1-23.
 [http://dx.doi.org/10.1016/j.ecl.2013.09.009] [PMID:  24582089]

[2]
Mendrick, D.L.; Diehl, A.M.; Topor, L.S.; Dietert, R.R.; Will, Y.; La Merrill, M.A.; Bouret, S.; Varma, V.; Hastings, K.L.; Schug, T.T.; Emeigh Hart, S.G.; Burleson, F.G. Metabolic syndrome and associated diseases: From the bench to the clinic. Toxicol. Sci.,  2018, 162(1), 36-42.
 [http://dx.doi.org/10.1093/toxsci/kfx233] [PMID:  29106690]

[3]
Huang, P.L. A comprehensive definition for metabolic syndrome. Dis. Model. Mech.,  2009, 2(5-6), 231-237.
 [http://dx.doi.org/10.1242/dmm.001180] [PMID:  19407331]

[4]
Chawla, R.; Jaggi, S. Medical management of diabesity. J. Assoc. Physicians India,  2019, 67(12), 52-56.
 [PMID:  31801332]

[5]
Hameed, M.; Khan, K.; Salman, S.; Mehmood, N. Dose comparison and side effect profile of metformin extended release versus metformin immediate release. J. Ayub Med. Coll. Abbottabad,  2017, 29(2), 225-229.
 [PMID:  28718236]

[6]
Mazidi, M.; Rezaie, P.; Kengne, A.P.; Mobarhan, M.G.; Ferns, G.A. Gut microbiome and metabolic syndrome. Diabetes Metab. Syndr.,  2016, 10(2)(Suppl. 1), S150-S157.
 [http://dx.doi.org/10.1016/j.dsx.2016.01.024] [PMID:  26916014]

[7]
Maruvada, P.; Leone, V.; Kaplan, L.M.; Chang, E.B. The human microbiome and obesity: Moving beyond associations. Cell Host Microbe,  2017, 22(5), 589-599.
 [http://dx.doi.org/10.1016/j.chom.2017.10.005] [PMID:  29120742]

[8]
Weiss, G.A.; Hennet, T. Mechanisms and consequences of intestinal dysbiosis. Cell. Mol. Life Sci.,  2017, 74(16), 2959-2977.
 [http://dx.doi.org/10.1007/s00018-017-2509-x] [PMID:  28352996]

[9]
Lee, C.J.; Sears, C.L.; Maruthur, N. Gut microbiome and its role in obesity and insulin resistance. Ann. N. Y. Acad. Sci.,  2020, 1461(1), 37-52.
 [http://dx.doi.org/10.1111/nyas.14107] [PMID:  31087391]

[10]
Cresci, G.A.; Bawden, E. Gut microbiome: What we do and don’t know. Nutr. Clin. Pract.,  2015, 30(6), 734-746.
 [http://dx.doi.org/10.1177/0884533615609899] [PMID:  26449893]

[11]
Thursby, E.; Juge, N. Introduction to the human gut microbiota. Biochem. J.,  2017, 474(11), 1823-1836.
 [http://dx.doi.org/10.1042/BCJ20160510] [PMID:  28512250]

[12]
Cani, P.D. Human gut microbiome: Hopes, threats and promises. Gut,  2018, 67(9), 1716-1725.
 [http://dx.doi.org/10.1136/gutjnl-2018-316723] [PMID:  29934437]

[13]
Sommer, F.; Anderson, J.M.; Bharti, R.; Raes, J.; Rosenstiel, P. The resilience of the intestinal microbiota influences health and disease. Nat. Rev. Microbiol.,  2017, 15(10), 630-638.
 [http://dx.doi.org/10.1038/nrmicro.2017.58] [PMID:  28626231]

[14]
Singh, R.K.; Chang, H.W.; Yan, D.; Lee, K.M.; Ucmak, D.; Wong, K.; Abrouk, M.; Farahnik, B.; Nakamura, M.; Zhu, T.H.; Bhutani, T.; Liao, W. Influence of diet on the gut microbiome and implications for human health. J. Transl. Med.,  2017, 15(1), 73.
 [http://dx.doi.org/10.1186/s12967-017-1175-y] [PMID:  28388917]

[15]
Schnack, L.L.; Romani, A.M.P. The metabolic syndrome and the relevance of nutrients for its onset. Recent Pat. Biotechnol.,  2017, 11(2), 101-119.
 [http://dx.doi.org/10.2174/1872208311666170227112013] [PMID:  28245777]

[16]
Toledo, G.V.; Mincer, T.; Bugarin, J.M.G.; DeWalt, J.; Schott, E.; Giron, M.J.S. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome. U.S. patent 10,596,209, 2020.

[17]
Vincent, C. Specific bacteria for their use as a medicament, in particular for controlling excess weight, obesity, cardiometabolic diseases, and inflammatory bowel diseases. U.S. Patent 10,681,932, 2020.

[18]
Backhed, F.; Karlsson, F.H.; Nielson, J.; Fagerberg, B.; Tremaroli, V. Identification of a person having risk for developing type 2 diabetes. U.S. Patent 9,881,135, 2018.

[19]
Kameyama, K.; Itoh, K. Diabetes-inducible bacterium. U.S. patents 10,597,427, 2020.

[20]
Brugere, J.F.; Borrel, G.; O’Toole, P.W.; Malpuech-Brugere, C.; Alric, M. Use of microorganisms for reducing the level of trimethylamine in a human body cavity, in particular for the treatment of trimethylaminuria or of bacterial vaginosis and the prevention of cardiovascular diseases. U.S. patent 10,238,695, 2019.

[21]
Cutcliffe, C.; Eid, J.S.; Bullard, J.H.; Schicklberger, M.F. Methods, and compositions relating to microbial treatment and diagnosis of disorders. United States patents US 10,675,312, 2020.

[22]
Venn-Watson, S.; Reiner, J.; Lumpkin, R. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome. U.S. patents 10,792,266, 2020.

[23]
Kimura, I.; Yamamoto, K.; Hisa, K. Composition for preventing or treating metabolism disorders comprising leuconostoc mesenteroides- producing exopolysaccharide as active ingredient. U.S. patent 10,792,302, 2020.

[24]
FitzGerald, M.J.; Spek, E.J. Microbiome therapeutics and patent protection. Nat. Biotechnol.,  2020, 38(7), 806-810.
 [http://dx.doi.org/10.1038/s41587-020-0579-z] [PMID:  32641843]

[25]
Butel, M.J. Probiotics, gut microbiota and health. Med. Mal. Infect.,  2014, 44(1), 1-8.
 [http://dx.doi.org/10.1016/j.medmal.2013.10.002] [PMID:  24290962]

[26]
de Cossío, L.F.; Fourrier, C.; Sauvant, J.; Everard, A.; Capuron, L.; Cani, P.D.; Layé, S.; Castanon, N. Impact of prebiotics on metabolic and behavioral alterations in a mouse model of metabolic syndrome. Brain Behav. Immun.,  2017, 64, 33-49.
 [http://dx.doi.org/10.1016/j.bbi.2016.12.022] [PMID:  28027925]

[27]
Marotz, C.A.; Zarrinpar, A. Treating obesity and metabolic syndrome with fecal microbiota transplantation. Yale J. Biol. Med.,  2016, 89(3), 383-388.
 [PMID:  27698622]

[28]
Aron-Wisnewsky, J.; Clément, K.; Nieuwdorp, M. Fecal microbiota transplantation: A future therapeutic option for obesity/diabetes? Curr. Diab. Rep.,  2019, 19(8), 51.
 [http://dx.doi.org/10.1007/s11892-019-1180-z] [PMID:  31250122]

[29]
Lee, E.S.; Song, E.J.; Nam, Y.D.; Lee, S.Y. Probiotics in human health and disease: From nutribiotics to pharmabiotics. J. Microbiol.,  2018, 56(11), 773-782.
 [http://dx.doi.org/10.1007/s12275-018-8293-y] [PMID:  30353462]

[30]
Fontané, L.; Benaiges, D.; Goday, A.; Llauradó, G.; Pedro-Botet, J. Influence of the microbiota and probiotics in obesity. Clin. Investig. Arterioscler.,  2018, 30(6), 271-279.
 [http://dx.doi.org/10.1016/j.artere.2018.10.002] [PMID:  29804899]

[31]
Torres, S.; Fabersani, E.; Marquez, A.; Gauffin-Cano, P. Adipose tissue inflammation and metabolic syndrome. The proactive role of probiotics. Eur. J. Nutr.,  2019, 58(1), 27-43.
 [http://dx.doi.org/10.1007/s00394-018-1790-2] [PMID:  30043184]

[32]
Grompone, G.; Derrien, M.; Van Hylckama Vlieg, J.; Serror, P.; Rigottier-Gois, L.; Crouzet, L.; Cherbuy, C. Use of Lactobacillus paracasei for promoting recovery of the intestinal microbiota diversity after dysbiosis. U.S. Patent 10,548,928, 2020.

[33]
Holzapfel, W.; Shin, H.; Hyun, C.K.; Ji, Y.; Park, S.; Kang, J. Lactobacillus plantarum HAC01 strain having anti-inflammatory efficacy and metabolic disease alleviating efficacy and use thereof. U.S. Patent 10,405,569, 2019.

[34]
Shen, J.; Wang, J.; Zhao, L.; Obin, M.S.; Derrien, M.; Rocher, E.; Hylckama Vlieg, J.V. Use of a Lactobacillus rhamnosus strain for reducing weight gain and/or insulin resistance. U.S. patent 10,022,407, 2018.

[35]
Huang, H.Y.; Chen, Y.H.; Hsieh, F.C. Composition and method of Lactobacillus reuteri GMNL-89 in treating type 2 diabetes. U.S. patent 9,301,983, 2016.

[36]
McLean, P.  Gonda, G.B.de; Collins, S.M.; Premysl, B.; Elena, V. de. B. Bifidobacterium longum and functional GI disorders. U.S. Patent 02,309,56, 2018.

[37]
Leser, T.D.; Myling, P.D.; Christensen, J.E.; Wellejus, A. Brockmann, Elke Probiotic Bifidobacterium adolescentis strains. U.S. Patent 10,022,408, 2018.

[38]
Burcelin, R.; Carcano, D.; Lahtinen, S.  Bifidobacteria for treating diabetes and related conditions. U.S. Patent 01,072,91, 2013.

[39]
Cani, P.; Everard, A.; Plovier, H.; Druart, C.; De Vos, W.; Belzer, C. Use of pasteurized Akkermansia for treating metabolic disorders. U.S. Patent 10,736,924, 2020.

[40]
Lesic, B.; Chambaud, I. Lactococcus lactis strains for use in improving digestive condition. E.P. Patent 26,514,23, 2015.

[41]
Lin, J.J. Pediococcus-based probiotics for body weight control. U.S. Patent 02, 460, 82, 2015.

[42]
Sugiyama, M.; Higashikawa, F.; Noda, M. Pediococcus pentosaceus lp28 for use in the prevention or amelioration of obesity. E. P. Patent 24,024,31, 2015.

[43]
Kelly, D.; Mulder, I. Bacterium for use as a probiotic for nutritional and medical applications. U.S. patent 02,791,77, 2018.

[44]
Knorr, R.; Cavadini, C.; Benyacoub, J.; Ebenezer, S. Probiotic enterococci for improved immunity. U.S. patent 00,987, 44, 2007.

[45]
Holscher, H.D. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes,  2017, 8(2), 172-184.
 [http://dx.doi.org/10.1080/19490976.2017.1290756] [PMID:  28165863]

[46]
An, X.; Bao, Q.; Di, S.; Zhao, Y.; Zhao, S.; Zhang, H.; Lian, F.; Tong, X. The interaction between the gut microbiota and herbal medicines. Biomed. Pharmacother.,  2019, 118, 109252.
 [http://dx.doi.org/10.1016/j.biopha.2019.109252] [PMID:  31545247]

[47]
Vasudevan, H.; Tait, A. Method of extracting flavonoids and polyphenols from dried and powdered citrus peels, compositions therefrom and method of treatment of diseases associated with chronic inflammation. U.S. patent 11,141,449, 2021.

[48]
Stahl, B.; Nauta, A.J.; Garssen, J.; Samain, E.; Drouillard, S. Fucosyllactose as breast milk identical non digestible oligosaccharide with new functional benefit. U.S. Patent 11,135,290, 2021.

[49]
Noel, S.P.; Shumpert, J.K.; Greene, A.; Austin, W.B. Biopolymer compositions for the treatment and prevention of liver disease. U.S. patent 11,116,809, 2021.

[50]
Tzortzis, G.; Vulevic, J. Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome. U.S. patent 11,052,097, 2021.

[51]
McConnell, B.; Elison, E. Composition comprising HMSS/HMOS and use thereof. U.S. patent 11,040,049, 2021.

[52]
McConnell, B. Synthetic composition for treating metabolic disorders. U.S. patent 10,881,674, 2021.

[53]
Von, M.G.A.; Silverman, J.; Yamanaka, Y.J.; Milwid, J.M.; Geremia, J.M.  Glycan therapeutics and related methods thereof. U.S. patent 10,702,542 2020.

[54]
Petschow, B.W.; McMahon, R.J.; Gibson, G.R.; Rastall, R.A.; Gemmell, R.; Saarela, M.; Aura, A.M. Nutritional composition having prebiotic. U.S. Patent 8,557,320, 2013.

[55]
Ferrarese, R.; Ceresola, E.R.; Preti, A.; Canducci, F. Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era. Eur. Rev. Med. Pharmacol. Sci.,  2018, 22(21), 7588-7605.
 [PMID:  30468509]

[56]
Cheruvanky, R.; Cherukuri, R.; Pecha, R.; Eliot, D. Synbiotics. U.S. patent 00,935,92, 2006.

[57]
Watson, T.S.; Watson, B.F. Probiotic formulation. U.S. Patent 6,468,525, 2002.

[58]
Hoon, K.J.; Jae, K.Y.; Won, P.S. Synbiotic food composition containing tagatose and probiotic lactic acid bacteria. E.P. Patent 28,372,92, 2017.

[59]
Lee, P.; Yacyshyn, B.R.; Yacyshyn, M.B. Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT). Diabetes Obes. Metab.,  2019, 21(3), 479-490.
 [http://dx.doi.org/10.1111/dom.13561] [PMID:  30328245]

[60]
Hegge, F.T.; Casen, C.; Valeur, J.; Roseth, A.; Smastuen, M.C. Companion diagnostic method for use in the treatment of irritable bowel syndrome with dietary interventions or faecal microbiota transplant. U.S. Patent 10,794,909, 2020.

[61]
Subhadra, B. Devices, systems and methods for the production of humanized gut commensal microbiota. U.S. Patent 10,767,157, 2020.

[62]
Borody, T. Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them. U.S. Patent 10,675,309, 2020.

[63]
Jones, L.A.; Jones, C.R.; Hlavka, E.J.; Gordon, R.D. Microbiota restoration therapy (MRT), compositions and methods of manufacture. U.S. patent 10,624,932, 2020.

[64]
Dominguez, B.; Maria, G. Methods for restoring microbiota of newborns. U.S. Patent 10,357,521, 2019.

[65]
Sadowsky, M.J.; Khoruts, A.; Weingarden, A.R.; Hamilton, M.J. Compositions and methods for transplantation of colon microbiota. U.S. patent 10,286,012, 2019.

[66]
Von, M.G.; Henn, M.R.; Cook, D.N.; Berry, D.A.; Afeyan, N.B.; Goodman, B.; McKenzie, M.J.L.; Vulic, M. Methods of populating a gastrointestinal tract. U.S. patent 10,064,900, 2018.

[67]
Heiman, M.L.; Stull, D.P.; Peno, J.W. Method to treat diabetes utilizing a gastrointestinal microbiome modulating composition. U.S. patent 9,040,101, 2015.

Rights & Permissions Print Cite

Article Metrics

7

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/2212798412666220318162322	Print ISSN 2772-574X
Publisher Name Bentham Science Publisher	Online ISSN 2772-5758

Recent Advances in Food, Nutrition & Agriculture

Therapeutic Effects of Gut Microbiota on Metabolic Syndrome: A Patent Review

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract